eligibility_summary
Eligibility: Untreated, histologically confirmed DLBCL with double expression (MYC≥40%, BCL2≥50%), age >70 or ≥65 with ECOG≥2, ≥1 measurable lesion (LN >1.5 cm or extranodal >1.0 cm, two diameters), ECOG ≤3, life expectancy ≥3 months, consent and compliance. Exclude: PCNSL, PMBCL, EBV+ DLBCL, HGBL, HLH, CNS involvement, concurrent/recent trials (<4 wks), HIV, major surgery <28 d, active infection <14 d, investigator-unsuitable.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Phase 2, single-arm trial in elderly double-expressor DLBCL (MYC/BCL2 overexpression) uses RLC induction (rituximab + lenalidomide + chidamide), then CR‑miniCHOP, with chidamide maintenance. Drugs/mechanisms: rituximab (anti‑CD20 monoclonal antibody) depletes B cells via ADCC/CDC/apoptosis, lenalidomide (IMiD) binds cereblon to degrade IKZF1/3, boosting T/NK activity and anti-lymphoma immunity, modulating NF‑κB/IRF4 signaling, chidamide/tucidinostat (oral selective HDAC inhibitor, class I/IIb) drives epigenetic reprogramming to promote apoptosis and antigen presentation. CHOP cytotoxics: cyclophosphamide (DNA alkylator), epirubicin/liposomal doxorubicin (anthracycline, topoisomerase II inhibitor), vindesine (vinca, microtubule inhibitor), prednisone (lympholytic corticosteroid). Targets/pathways: CD20+ malignant B cells, cereblon–IKZF axis, HDAC/epigenetic control, DNA damage and mitotic spindle—aimed at overcoming MYC/BCL2-driven survival.